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ABSTRACT 
A group of thirty-nine stilbene derivatives, prepared by means of Heck coupling reactions, has been 
investigated for their cytotoxicity, as well as for their ability to inhibit the production of the vascular 
endothelial growth factor (VEGF) and the activation of telomerase. The ability of these compounds to 
inhibit proliferation of two tumoral cell lines (HT-29 and MCF-7) and one non tumoral cell line (HEK-
293) was first determined. Subsequently, we determined the capacity of the compounds to inhibit the 
secretion of VEGF in the aforementioned cell lines and to downregulate the expression of the VEGF, h-
TERT and c-Myc genes, the two latter involved in the control of the activation of telomerase. One of the 
synthetic stilbenes, (E)-4-(4-methoxystyryl)aniline, showed strong cytotoxicity and proved able to 
cause a marked decrease both in the secretion of VEGF and in the expression of the h-TERT and c-Myc 
genes, in all cases at concentrations in the low nanomolar range. 
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1. Introduction 
Resveratrol, a natural compound belonging to the class of stilbenes (Fig. 1) is a polyphenolic 
compound which occurs in grapes, red wine, chocolate, and certain berries and roots. It became popular 
since the 1993 paper on its inhibitory effects against the oxidation of human low-density lipoproteins, a 
chemical event at the onset of the pathogenesis of atherosclerosis [1]. In later years, further important 
biological features were reported for the compound, most particularly antioxidant, anticarcinogenic, 
and anti-inflammatory properties [2]. These properties were related to the ability of the compound to 
retard the onset of age-related diseases [3] and to its beneficial effect on other ailments such as viral 
attacks [4], diabetes [5], inflammation [6] and neurodegenerative diseases [7]. In addition, resveratrol 
has been shown to display, among other features: a) cancer chemopreventive effects by means of 
inhibiting the initiation step of the carcinogenesis process [8]; b) anticancer activity through inhibition 
of cell cycle progression and induction of apoptotic cell death [9]; and c) antiangiogenic activity with 
sufficient potency to suppress FGF-2 and VEGF-induced neovascularisation in vivo [10] and to inhibit 
bovine aorta endothelial cell proliferation, migration and tube formation in vitro [11]. 
 
Figure 1. Structure of resveratrol 
Tumor angiogenesis is a very complex process and involves the tight interplay of many factors [12]. 
Vascular endothelial growth factor (VEGF) is an inducer of angiogenesis and promotes endothelial cell 
survival, proliferation and migration while increasing vascular permeability [13]. In fact, 
overexpression in the production of VEGF has been reported to occur in various types of tumors [14]. 
Not unexpectedly, VEGF has become one further key target molecule in cancer therapy [15,16]. 
Cancer cells are able to evolve the ability to overcome senescence upon telomerase reactivation 
[17]. This enzyme has been detected in about 90% of all malignant tumors [18], so that drugs with 
ability to inhibit telomerase activity are potentially useful weapons in the fight against cancer, aging 
and other diseases related to premature telomere shortening [19]. Recently, it has been reported that 
resveratrol downregulates the telomerase activity of MCF-7 cells and the nuclear levels of hTERT, the 
reverse transcriptase subunit of the telomerase complex [20]. 
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2. Research purpose 
When aiming at a more efficient anticancer therapy, compounds exhibiting not only high cytotoxic 
activity but also the ability to suppress tumoral angiogenesis and the expression of genes related to 
telomerase activation would be highly desirable [21]. On our ongoing research on anticancer properties 
of synthetic analogues derived from natural products, we have recently reported on the inhibition of 
VEGF formation in cancer cells and on endothelial cell differentiation promoted by synthetic stilbene 
derivatives [22]. Our study has established that resveratrol and several stilbene derivatives lead to a 
decrease in the production of VEGF by HT-29 cells. In view of these precedents we decided to evaluate 
the influence of new synthetic stilbene analogues not only on VEGF production, but also on the 
expression of the hTERT gene, involved in the process of telomerase activation. In addition, we further 
decided to measure the inhibition of expression of c-Myc, an oncogene which encodes the c-Myc 
protein that acts as a transcription factor for hTERT expression. 
The structures of the synthetic resveratrol analogues which are the subject of this work are depicted 
in Figure 2. These compounds belong to two types: one corresponds to stilbenes carrying hydroxy 
and/or methoxy groups (a-series in Figure 2), whereas the other (b-series) includes stilbenes carrying 
amine or amide functions in one of the rings, as well as hydroxyl or methoxy groups in the other. 
 
 
1a  R1 = 2-OH   R2 = 2´-OH 6a  R1 = 4-OH    R2 = 4´-OH 11a  R1 = 3-OMe   R2 = 3´-OH 
2a  R1 = 3-OH   R2 = 2´-OH 7a  R1 = 2-OMe  R2 = 2´-OH 12a  R1 = 4-OMe   R2 = 3´-OH 
3a  R1 = 4-OH   R2 = 2´-OH 8a  R1 = 3-OMe  R2 = 2´-OH 13a  R1 = 2-OMe   R2 = 4´-OH 
4a  R1 = 3-OH   R2 = 3´-OH 9a  R1 = 4-OMe  R2 = 2´-OH 14a  R1 = 3-OMe   R2 = 4´-OH 
5a  R1 = 4-OH   R2 = 3´-OH 10a  R1 = 2-OMe  R2 = 3´-OH 15a  R1 = 4-OMe   R2 = 4´-OH 
1b  R1 = 2-NH2  R2 = H 9b  R1 = 3-NH2   R2 = 4´-OH 17b  R1 = 3-NH2    R2 = 3´-OMe 
2b  R1 = 3-NH2  R2 = H 10b  R1 = 4-NH2   R2 = 2´-OH 18b  R1 = 3-NH2    R2 = 4´-OMe 
3b  R1 = 4-NH2  R2 = H 11b  R1 = 4-NH2   R2 = 3´-OH 19b  R1 = 4-NH2    R2 = 2´-OMe 
4b  R1 = 2-NH2  R2 = 2´-OH 12b  R1 = 4-NH2   R2 = 4´-OH 20b  R1 = 4-NH2    R2 = 3´-OMe 
5b  R1 = 2-NH2  R2 = 3´-OH 13b  R1 = 2-NH2   R2 = 2´-OMe 21b  R1 = 4-NH2     R2 = 4´-OMe 
6b  R1 = 2-NH2  R2 = 4´-OH 14b  R1 = 2-NH2   R2 = 3´-OMe 22b  R1 = 2-NHCO(CH2)10Me   R2 = H 
7b  R1 = 3-NH2  R2 = 2´-OH 15b  R1 = 2-NH2   R2 = 4´-OMe 23b  R1 = 3-NHCO(CH2)10Me   R2 = H 
8b  R1 = 3-NH2  R2 = 3´-OH 16b  R1 = 3-NH2   R2 = 2´-OMe 24b  R1 = 4-NHCO(CH2)10Me   R2 = H 
Figure 2. Structures of synthetic resveratrol analogues. 
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3. Synthetic work 
Stilbene derivatives 1a-15a were prepared by means of palladium-catalyzed Heck-type cross 
coupling reactions [23]. Monohydroxylated styrenes were used as the nucleophilic partners whereas 
hydroxy or methoxy bromobenzenes played the role of the electrophilic components, with Pd(PPh3)4 
being the catalyst [24] (conditions A in Scheme 1). These reactions were performed under microwave 
irradiation, as these conditions have often been found to accelerate this kind of coupling reactions [25] 
(for details and yields, see Experimental section).  
 
Scheme 1. Synthesis of stilbene derivatives by means of palladium-catalyzed Heck couplings (for more 
detailed descriptions of the reaction conditions and yields, see Supporting Information). 
 
Preparation of compounds belonging to the b-series was also carried out with Heck-type cross 
coupling reactions. The same type of nucleophilic partners as above were used, with the electrophilic 
components being now bromoanilines. The aforementioned reaction conditions A, however, used in the 
synthesis of compounds of the a-series, were successful in the preparation of some compounds (e. g. 
4b, 5b, 7b, 9b), but proved inefficient in other cases or else failed completely. In order to obtain the 
remaining amino stilbenes without protection of the amino groups, we undertook a survey of catalysts 
and conditions which resulted in three new reactions conditions, B, C and D (Scheme 1). In this case, 
Pd(NH3)2Cl2 was the catalyst [26], the differences residing in the reaction conditions. All Heck 
reactions were highly stereoselective and afforded, after chromatographic purification, the 
corresponding stilbenes of E-configuration with no traces of Z-isomers. Yields ranged from 50% to 
88% and, most importantly, no protection/deprotection steps were needed. 
 
Amides 22b-24b were prepared with the aim at observing whether the introduction of a lipophilic 
side chain would cause visible changes in the biological properties. Amide 23b was synthesized upon 
 6
coupling compound 2b with dodecanoic acid in the presence of chlorosulfonyl isocyanate [27]. 
Attempts at preparing 22b and 24b in the same way by means of acylation of 1b and 3b, respectively, 
were unsatisfactory. Thus, 22b and 24b were obtained by first acylating the corresponding 
bromoaniline followed by Heck coupling of the resulting amide with styrene under conditions C. 
4. Biological work 
4.1. Inhibition of cell proliferation 
We carried out a measurement of the cytotoxic activity of our synthetic stilbenes using two tumoral 
cells, the human colon HT-29 and the breast adenocarcinoma MCF-7 cell lines, as well as one non 
tumoral cell line, the human embryonic kidney cell line, HEK-293 [28]. Table 1 shows cytotoxicity 
values for stilbenes of the a-series, expressed as the compound concentration (µg/mL) that causes 50% 
inhibition of cell growth (IC50). Table 1 further shows the  and  coefficients, obtained by dividing 
the IC50 values of the normal cell line by those of either the HT-29 or the MCF-7 cell line, respectively 
(see footnote in Table 1). The higher the value of either coefficient, the higher the therapeutic safety 
margin of the compound in the corresponding cell line. 
Table 1. IC50 values (µg/mL) and selectivity coefficients for compounds of the a-series. 
Compound HT-29 MCF-7 HEK-293 b c
Resveratrol 34.1 ± 1.4 16.1 ± 1.1 7.1 ± 1.0 0.2 0.4 
1a 25± 7 23.0 ± 1.3 24.3 ± 2.3 0.9 1.1 
2a 27 ± 7 20.1 ± 2.1 18 ± 8 0.7 0.9 
3a 22 ± 9 21 ± 3 17.5 ± 1.5 0.8 0.8 
4a 25.9 ± 1.0 21 ± 6 21 ± 5 0.8 1 
5a 6.9 ± 1.9 23 ± 3 1.1 ± 0.7 0.2 < 0.1 
6a >100 6.8 ± 0.2 1.2 ± 0.1 < 0.1 0.2 
7a 23 ± 6 17.9 ± 2.4 15.0 ± 2.5 0.7 0.8 
8a 26 ± 3 18 ± 4 20 ± 4 0.8 1.1 
9a 10 ± 4 17 ± 6 21 ± 4 2.1 1.2 
10a 17 ± 4 24.3 ± 1.0 24 ± 3 1.4 1 
11a 11.5 ± 3 13 ± 3 19 ± 7 1.6 1.5 
12a 22 ± 4 21 ± 5 24 ± 3 1.1 1.1 
13a 24 ± 3 19 ± 4 41 ± 3 1.7 2.2 
14a 26 ± 4 21.0 ± 1.5 24 ± 3 0.9 1.1 
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15a 17.4 ± 0.2 11.3 ± 2.3 3.9 ± 0.5 0.2 0.3 
aValues are the average ( s.d.) of three different measurements performed as described in the Material 
and Methods section. b = IC50 (HEK-293) / IC50 (HT-29). c = IC50 (HEK-293) / IC50 (MCF-7). Values 
of  and  have been rounded off to a decimal figure. 
 
The observed values for IC50 are in the low to medium micromolar range, with compound 5a 
showing the lowest values in the HT-29 cell line and compound 6a showing the lowest values in the 
MCF-7 cell line. In the case of HT-29 cell lines, all synthetic compounds exhibit better IC50 values than 
resveratrol. As regards the  and  coefficients, the calculated values are is most cases close to, or even 
lower than 1. This means that the cytotoxic activity of these compounds is similar in both the non 
tumoral and the tumoral line. 
Table 2. IC50 values (g/mL) and selectivity coefficients for compounds of the b-series. 
Compound HT-29 MCF-7 HEK-293 b c
Resveratrol 34.1 ± 1.4 16.1 ± 1.1 7.1 ± 1.0 0.2 0.4 
1b 17 ± 4 1.4 ± 0.1 1.3 ± 0.2 0.1 0.9 
2b 12.9 ± 0.9 14 ± 4 84 ± 11 6.5 6 
3b 4.4 ± 1.1 16 ± 0.1 11.4 ± 0.4 2.6 0.7 
4b 36 ± 5 39 ± 3 27 ± 7 0.7 0.7 
5b 30 ± 5 17 ± 3 20 ± 7 0.7 1.2 
6b >100 79 ± 3 7 ± 3 < 0.1 < 0.1 
7b 30.4 ± 1.8 24.7 ± 0.2 96 ± 15 3.2 3.9 
8b 43 ± 16 54 ± 7 >100 2.3 1.8 
9b 51 ± 16 6 ± 3 7 ± 3 0.1 1.2 
10b 37 ± 5 23 ± 4 21.4 ± 1.4 0.6 1 
11b 42 ± 6 24.8 ± 0.4 25 ± 8 0.6 1 
12b 30.6 ± 2.4 2.2 ± 0.4 0.8 ± 0.1 0.03 0.4 
13b >100 >100 2.1 ± 0.7 < 0.1 < 0.1 
14b 21.2 ± 1.5 6.1 ± 1.8 0.5 ± 0.1 < 0.1 < 0.1 
15b 73 ± 5 0.4 ± 0.1 0.6 ± 0.1 < 0.1 1.4 
16b 25.3 ± 0.1 38.7 ± 0.6 45 ± 0.3 1.8 1.2 
17b 19.6 ± 2.0 34 ± 5 16 ± 5 0.8 0.5 
18b 16.3 ± 0.4 23 ± 4 11 ± 0.3 0.7 0.5 
19b 22 ± 4 3.2 ± 1.7 1 ± 0.3 < 0.1 0.3 
20b 16.1 ± 0.1 52 ± 6 18 ± 4 1.1 0.3 
21b 0.0036 ± 0.0015 0.0021 ± 0.0005 0.012 ± 0.004 3.4 5.7 
22b 2.5 ± 0.7 12 ± 0.9 16 ± 9 6.4 1.3 
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23b >100 3.5 ±0.5 11.6 ± 0.6 < 0.1 3.3 
24b >100 5.8 ± 0.1 10 ± 4 < 0.1 1.7 
aValues are the average ( s.d.) of three different measurements performed as described in the Material 
and Methods section. b = IC50 (HEK-293) / IC50 (HT-29). c = IC50 (HEK-293) / IC50 (MCF-7). Values 
of  and  have been rounded off to a decimal figure. 
 
Cytotoxicity values for stilbenes of the b-series are shown in Table 2, with most compounds 
showing cytotoxicities of the same order of magnitude as those of Table 1. It can be further observed 
that the introduction of the aliphatic side chains (compounds 22b-24b) did not cause improvements in 
the cytotoxic activities. However, one of the stilbene derivatives calls for attention: compound 21b 
showed cytotoxic values in the low nanomolar range for both cancer cell lines. The  and  
coefficients, clearly above 1, further show that the compound is noticeably more cytotoxic for tumoral 
cell lines than for normal ones, a desirable feature. 
4.2. Effect of stilbene derivatives on VEGF protein secretion and VEGF gene inhibition 
The action of stilbene derivatives on VEGF secretion and VEGF gene inhibition was conducted on 
the HT-29 tumoral cell line. For these measurements compounds 9a-13a, 2b, 3b, 7b, 8b, 16b and 20b-
22b were selected because they had-coefficients above 1. In addition, compounds 1b, 14b, 17b and 
18b were further selected because they had lower IC50 values than resveratrol. 
The secretion of the vascular endothelial growth factor (VEGF) was first determined by means of 
the ELISA procedure [29], as described in the Experimental Section. Results for all the selected 
compounds (except 21b, which will be discussed later) are depicted in Figure 3, which shows the 
percentage of VEGF secreted to the culture medium after 72 h of incubation in the presence of DMSO 
(control experiment) and in the presence of each of the compounds investigated at a concentration of 10 
g/mL (lower than their IC50 values). 
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Figure 3. VEGF protein secretion from HT-29 cells determined by means of the ELISA procedure. At 
least three measurements were performed in each case. Concentration of all compounds was 10 g/mL. 
Bars represent mean values of VEGF secretion (percentage values related to control) and error bars 
indicate standard errors of the mean. The statistical significance was evaluated using one-sample t-tests 
(P < 0.001). 
 
While the majority of the compounds showed an inhibitory effect on VEGF production, the values 
were very similar to that of resveratrol, which reduced VEGF secretion to 78% of the control value. 
The most active is compound 14b, which causes a decrease to 51%. 
The high cytotoxicity of compound 21b, as compared with the remaining stilbenes, justified a 
separate study. It was evaluated as regards inhibition of VEGF production on both the HT-29 and the 
MCF-7 cell line (Figure 4). When a concentration of 1 ng/mL was used, no noticeable effect on VEGF 
production was detected in either of the two cell lines. However, at 2 ng/mL concentration, compound 
21b inhibited VEGF secretion to 84% of the control value in the case of HT-29 cells and to 75% in the 
case of MCF-7. When HT-29 cells were cultivated in the presence of 3 ng/mL of compound 21b, 
VEGF protein secretion further dropped to 59%. These values are similar to that achieved by 
resveratrol at a concentration of 10 g/mL. Compound 21b therefore is three orders of magnitude 
more active than resveratrol in inhibiting VEGF production. 
 10
 
Figure 4. VEGF protein secretion from HT-29 and MCF-7 cells with compound 21b as determined by 
means of the RT-qPCR methodology. At least three measurements were performed in each case. 
Concentration of resveratrol was 10 g/mL. Bars represent mean values of VEGF secretion (percentage 
values related to control) and error bars indicate standard errors of the mean. The statistical significance 
was evaluated using one-sample t-tests (P < 0.001). 
 
While the results depicted in Figures 3 and 4 point out that the investigated compounds cause 
inhibition of the VEGF production, they do not permit conclusions about the precise phase of the 
VEGF generation process with which they interfere. In order to further investigate the mechanism of 
action of the compounds under study, we proceeded to determine whether they were able to control 
protein production at the transcriptional level. The VEGF production we have determined with the 
ELISA procedure is that secreted to the culture medium and corresponds mainly to the lighter VEGFA-
165 isoform [30]. Therefore, in order to evaluate the ability of our compounds to inhibit the expression 
of the VEGF gene, we incubated HT-29 cells for 48 h with several selected stilbene derivatives at a 
concentration of 10 g/mL, again with DMSO as the control test. For that purpose, the reverse 
transcription quantitative PCR (RT-qPCR) methodology [31] was used as described in the 
Experimental Section. Results for all the selected compounds (except 21b) are shown in Figure 5 as 
percentage of the VEGF gene expression. All values were standardized (100%) to control (DMSO) and 
to -actine. 
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Figure 5. Expression percentage of the VEGF gene after 48 h of incubation of HT-29 cells determined 
by means of the RT-qPCR methodology. At least three measurements were performed in each case. 
Concentration of all compounds was 10 g/mL. Error bars indicate standard errors of the mean. The 
statistical significance was evaluated using one-sample t-tests (P < 0.001). 
 
Comparison of Fig. 5 with Fig. 4 reveals much more meaningful differences in activity between the 
compounds investigated. Thus, several compounds showed a visibly stronger inhibitory effect on the 
transcription of VEGF mRNA than resveratrol, which lowered VEGF gene expression to 65% of the 
control value. The reduction degrees were particularly strong for compounds 3b and 17b, which caused 
inhibition of the gene expression to 24% and 23%, respectively, of the control value. 
The results displayed in Figs. 4 and 5 do not show correlation between the VEGF amount excreted 
to the medium and the degree of gene expression. Compounds 3b and 17b, for instance, proved highly 
effective in the inhibition of the VEGF gene expression but much less so in decreasing the amount of 
VEGF secreted to the medium. This suggests that these compounds exert the control of VEGF 
production at a phase different from that of gene transcription, perhaps during the post-translational 
stage, during which the lighter isoforms such as VEGFA-165 are formed and secreted to the medium 
[30]. 
As in the previous case, a separate study was performed for compound 21b. The inhibition of the 
VEGF gene expression was measured in this case on both HT-29 and MCF-7 cancer cell lines, the 
results being depicted in Figure 6. When HT-29 cells were incubated in the presence of 1, 2 or 3 ng/mL 
of compound 21b, the level of VEGF gene expression was similar to that achieved with resveratrol at a 
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concentration of 10 g/mL In other words, the potency of compound 21b in downregulating VEGF 
gene expression is three orders of magnitude higher than that of resveratrol. In addition, when MCF-7 
cells were treated with 2 ng/mL of compound 21b, only 36 % of VEGF gene expression was detected. 
Thus, compound 21b is about 5000 times more active than resveratrol. 
 
Figure 6. Expression percentage of the VEGF gene after 48 h of incubation of HT-29 and MCF-7 
cells with compound 21b as determined by means of the RT-qPCR methodology. At least three 
measurements were performed in each case. Concentration of resveratrol was 10 g/mL. Error bars 
indicate standard errors of the mean. The statistical significance was evaluated using one-sample t-
tests (P < 0.001). 
 
4.3. Effect of stilbene derivatives on the inhibition of the hTERT and c-Myc genes 
Human telomerase contains an RNA component (hTERC) that serves as a template for the addition 
of the repeat nucleotide sequences and also a reverse transcriptase subunit (hTERT) which catalyzes 
the nucleotide polymerization process. In addition, there are other associated protein factors, the role of 
which has not yet been completely elucidated. Human telomerase is regulated during development and 
differentiation, mainly through transcriptional control of the hTERT gene, the expression of which is 
restricted to cells that exhibit telomerase activity. This indicates that the hTERT subunit is the rate 
limiting factor of the enzyme complex. For the expression of the hTERT gene, several transcriptional 
factors such as c-Myc, a proto-oncoprotein [32], have been found to play an important role through 
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upregulation of the mRNA encoding the hTERT protein subunit [33]. Thus, and as an initial study of 
the potential activity of these stilbene derivatives as inhibitors of telomerase activation, we have 
investigated their ability to inhibit the expression of the hTERT and c-Myc genes, which are responsible 
for the production of the corresponding proteins. 
In order to determine whether the studied compounds were able to regulate the expression of the two 
aforementioned genes, we have performed a RT-qPCR analysis using again HT-29 tumoral cells. The 
cells were incubated for 48 h in the presence of DMSO (control) and 10 g/mL of each of the studied 
compounds (lower than the IC50 values). Results are depicted in Fig. 7 (hTERT gene expression) and 
Fig. 8 (c-Myc gene expression). As in previous experiments, the highly cytotoxic compound 21b was 
the subject of a separate study, which will be described below. 
 
Figure 7. Expression percentage of the hTERT gene after 48 h of incubation with HT-29 cells as 
determined by means of the RT-qPCR methodology. At least three measurements were performed in 
each case. Concentration of all compounds was 10 g/mL. Bars represent mean values of VEGF 
secretion (percentage values related to control) and error bars indicate standard errors of the mean. The 
statistical significance was evaluated using one-sample t-tests (P < 0.001). 
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Figure 8. Expression percentage of the c-Myc gene after 48 h of incubation with HT-29 cells as 
determined by means of the RT-qPCR methodology. At least three measurements were performed in 
each case. Concentration of all compounds was 10 g/mL. Bars represent mean values of VEGF 
secretion (percentage values related to control) and error bars indicate standard errors of the mean. The 
statistical significance was evaluated using one-sample t-tests (P < 0.001). 
 
As shown in Fig. 7, compounds 10a-12a, 3b, 7b, 14b, 16b and 22b showed the highest ability to 
downregulate the expression of the hTERT gene, their activities being somewhat higher than that of 
resveratrol. As regards the expression of the c-Myc gene (Fig. 8), more or less the same compounds 
showed the highest inhibitory activity. In any case, however, differences in activity with resveratrol 
were perceptible but not particularly worth noting. 
Inhibition of h-TERT and c-Myc gene expression for compound 21b was measured on both HT-29 
and MCF-7 cancer cell lines. Results are shown in Figs. 9 and 10, which show that compound 21b was 
able to downregulate the expression of the h-TERT and c-Myc genes. The expression of the h-TERT 
gene was decreased to 48% of the control value when 3 ng/mL concentration was used on HT-29 cells, 
and to 51% when 2 ng/mL concentration was used on MCF-7 cells. Again, the potency of compound 
21b in downregulating the h-TERT and c-Myc genes is 3000-5000 times greater than that of resveratrol. 
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Figure 9. Expression percentage of the hTERT gene after 48 h of incubation with compound 21b as 
determined by means of the RT-qPCR methodology. At least three measurements were performed in 
each case. Concentration of resveratrol was 10 g/mL. Bars represent mean values of VEGF secretion 
(percentage values related to control) and error bars indicate standard errors of the mean. The statistical 
significance was evaluated using one-sample t-tests (P < 0.001). 
 
Figure 10. Expression percentage of the c-Myc gene after 48 h of incubation of HT-29 and MCF-7 
cells with compound 21b as determined by means of the RT-qPCR methodology. At least three 
measurements were performed in each case. Concentration of resveratrol was 10 g/mL. Bars represent 
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mean values of VEGF secretion (percentage values related to control) and error bars indicate standard 
errors of the mean. The statistical significance was evaluated using one-sample t-tests (P < 0.001). 
 
Table 3 summarizes the results observed for the synthetic compounds 12a, 3b, 7b, 14b, 16b, 17b, 
21b and 22b, as well as for resveratrol. As regards inhibition of the expression of the VEGF, hTERT 
and c-Myc genes, stilbene derivatives bearing amino groups (b-series) feature much better than those 
lacking them (a-series). Within stilbenes carrying an amide function, the most active is compound 22b 
whereas within amino stilbenes, those having a methoxy group (14b, 16b, 17b and 21b) perform better 
than those having a hydroxy group. A very particular case is compound 21b, which is able to 
downregulate the secretion of VEGF protein and the expression of VEGF, h-TERT and c-Myc genes at 
concentrations in the low nanomolar level. 
 
Table 3. Compared percentages of excretion of the VEGF protein and of the expression of the VEGF, 
hTERT and c-Myc genes.a 
 
Compd 
Cytotoxicity 
(IC50, g/mL) 
% Secretion of 
VEGF protein 
% Expression 
of VEGF gene 
% Expression 
of hTERT gene 
% Expression 
of c-Myc gene 
Resv. 34.1 ± 1.4 78 65 57 51 
12a 22 ± 4 73 38 48 46 
3b 4.4 ± 1.1 78 24 65 46 
7b 30.4 ± 1.8 76 38 52 37 
14b 21.2 ± 1.5 51 100 35 79 
16b 25.3 ± 1 75 67 52 45 
17b 19.6 ± 2 73 23 100 34 
21bb 0.0036 ± 0.001 59 67 48 69 
22b 2.5 ± 0.7 79 37 53 45 
 
aAll values refer to HT-29 cells. The values observed for the control (DMSO without added 
drugs) are taken as the 100% reference of protein excretion or gene expression. Therefore, the 
lower the value, the higher the activity of the drug in the corresponding activity. Except for 21b, 
measurements were performed at concentration values of 10 g/mL. 
bAt a concentration of 3 ng/mL. 
 
The biological activities of resveratrol are often ascribed, at least in part, to its antioxidant activity. 
The various biological activities of resveratrol analogues depend upon the number and location of the 
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hydroxy groups [34], minor structural changes in such stilbenes having major effects on their biological 
activity [35]. In the present study, a series of 39 stilbenes carrying hydroxy, methoxy and amino groups 
were compared with resveratrol for their cytotoxicity and for their ability to inhibit VEGF secretion and 
the expression of the VEGF, h-TERT and c-Myc genes. Several compounds were found to be more 
active than resveratrol, the case of (E)-4-(4-methoxystyryl)aniline (21b) being particularly interesting 
because of its high cytotoxicity. In order to find some relationships between chemical structure and 
biological activity, we have graphically represented α coefficients vs. β coefficients of the studied 
compounds (Fig. 11). Figs. 11a to 11c display the and  values for stilbenes carrying an ortho-, meta- 
and para-hydroxy group, respectively. Figure 11d shows values for the remaining compounds. 
 
Figure 11. α coefficients vs. β coefficients of the synthetic stilbenes. 
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Figure 11 (cont.). α coefficients vs. β coefficients of the synthetic stilbenes. 
 
As mentioned above, the higher the coefficient values, the better the safety margin for the 
corresponding compound from the therapeutic point of view. Aside from compound 21b, which is three 
orders of magnitude more cytotoxic than the others, the best safety margins are achieved with 
compounds 9a (2’-OH, 4-OMe), 13a (4’-OH, 2-OMe), 7b (2’-OH, 3-NH2), 8b (3’-OH, 3-NH2) and 
16b (2’-OMe, 3-NH2). These three amino stilbenes share in common an amino group in meta position, 
regardless of the position occupied by the hydroxy or methoxy group. Compound 21b, however, which 
is cytotoxic at nanomolar level and shows the highest safety margins, has its amino group in the para 
position. This may possibly indicate that, in comparison with the rest of compounds, 21b shows a 
different mode of action. 
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In Figure 12, the percentage of VEFG protein secretion is graphically represented vs. the percentage 
of h-TERT gene expression. Compounds 14b and 21b are located in the lower left quadrant, where high 
inhibition of VEGF secretion and high inhibition of h-TERT gene expression are combined. It is worth 
noting that this desirable dual mode of action is exhibited by compound 21b at low nanomolar 
concentrations, whereas compound 14b achieves it only at the micromolar level. 
 
Figure 12. Percentage of VEFG protein secretion vs. percentage of h-TERT gene expression. 
5. Summary and conclusions 
In conclusion, 39 stilbene derivatives have been synthesized and evaluated for their biological 
activity. One of them, (E)-4-(4-methoxystyryl)aniline (compound 21b) has proven particularly 
interesting. Not only has this compound a strong cytotoxicity at the low nanomolar level and a good 
safety margin, it further combines these features with an ability to inhibit VEFG protein secretion and 
the expression of the telomerase related h-TERT and c-Myc genes at similarly low concentrations. 
Compound 21b therefore may possibly display anticancer activity through a multiple mode of action. It 
is worth noting that 21b shows an extremely high difference in activity with all other compounds, 
including its positional isomers 19b and 20b, and its demethyl derivative 12b. This may possibly 
suggest that its interactions with its (still unknown) biomolecular targets, and perhaps also the targets 
themselves, are of a different nature. More studies will be required to acquire a knowledge about its 
mechanism of action. 
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6. Experimental 
6.1. Chemistry. General procedures 
The general reaction conditions and the physical and spectral data of all synthetic intermediates and 
final compounds are described in detail in the Supporting Information. The samples of compounds used 
for the biological studies were purified to > 95% by means of preparative HPLC. 
6.2. Biological studies. Materials and methods 
6.2.1. Reagents and cell culture 
Cell culture media were purchased from Gibco (Grand Island, NY, USA). Fetal bovine serum (FBS) 
was a product of Harlan-Seralab (Belton, U.K.). Supplements and other chemicals not listed in this 
section were obtained from Sigma Chemicals Co. (St. Louis, Mo., USA). Plastics for cell culture were 
supplied by Thermo ScientificTM BioLite. All tested compounds were dissolved in DMSO at a 
concentration of 10 g/mL and stored at –20C until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose (1 
g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 µg/mL) and amphoterycin (1.25 
µg/mL), supplemented with 10% FBS. 
6.2.2. Cytotoxicity assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co., St. 
Louis, MO) dye reduction assay in 96-well microplates was used, as previously described [36]. Some 5 
x 103 cells of HT-29, MCF-7 or HEK-293 cells in a total volume of 100 µL of their respective growth 
media were incubated with serial dilutions of the tested compounds. After 3 days of incubation (37 C, 
5% CO2 in a humid atmosphere), 10 µl of MTT (5 mg/ml in PBS) were added to each well and the 
plate was incubated for further 4 h (37 C). The resulting formazan was dissolved in 150 µL of 0.04 N 
HCl/2-propanol and read at 550 nm. All determinations were carried out in triplicate. 
6.2.3. ELISA analysis 
HT-29 cells at 70–80% confluence were collected after serum starvation for 24 h. Cells were 
incubated with the selected stilbene derivatives in DMSO for 72 h (Fig. 3). Culture supernatants were 
collected and VEGF secreted by HT-29 cells was determined using Invitrogen Human Vascular 
Endothelial Growth Factor ELISA Kit according to the manufacturer’s instructions. 
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6.2.4. RT-qPCR analysis 
HT-29 cells at 70–80% confluence were collected after serum starvation for 24 h. Cells were 
incubated with 10 µg/mL of  the corresponding drugs in DMSO for 48 h. Cells were collected and the 
total cellular RNA from HT-29 cells was isolated using Ambion RNA extraction Kit according to the 
manufacturer’s instructions. The cDNA was synthesized by MMLV-RT with 1-21 g of extracted 
RNA and oligo(dT)15 according to the manufacturer’s instructions. 
Amplification of the genes was performed by use of a StepOnePlus™ thermalcycler. Fast TaqMan 
Gene Expression Master Mix containing the appropriate buffer for the amplification conditions, 
dNTPs, thermostable DNA polymerase enzyme and a passive reference probe was used. Each of the 
genes were amplified using predesigned primers by Life Technologies TaqMan® Gene Expression 
Assays, Hs99999903-m1 (-actin), Hs00900055-m1 (VEGF), Hs00972646-m1 (hTERT) and 
Hs00153408-m1 (c-Myc). 
6.2.5. Statistical analysis 
Data are expressed as the mean ± SEM. Statistical analyses were done using Microsoft Excel and 
GraphPad Prism®. Differences between means were determined using Student’s t-Test or one-way 
ANOVA with Dunnett's Multiple Comparison Test, and considered to be statistically significant at 
p≤0.001. 
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